André T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16. Abstract

Gallen M et al. Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial. J Clin Oncol 2013;31(12):1609. Abstract

Love N et al. Is adjuvant oxaliplatin (Ox) overutilized in colon cancer (CC)? 408 cases from the practices of 102 oncologists. Gastrointestinal Cancers Symposium 2013;Abstract 479.

Mayer RJ. Oxaliplatin as part of adjuvant therapy for colon cancer: More complicated than once thought. J Clin Oncol 2012;30:3325-7. Abstract

Tabernero J. Results from the MOSAIC trial subgroup analysis of adjuvant 5-FU and oxaliplatin in Stage II colon cancer and elderly patients and the use of oxaliplatin in Stage II and Stage III colon cancer. Gastrointestinal Cancer Update, Issue 2, 2013. Available at: http://www.researchtopractice.com/GICU113/josep-tabernero-md/results-mosaic-trial-subgroup-analysis-adjuvant-5-fu-and-oxaliplatin-stag.

Tournigand C et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30(27):3353-60. Abstract

Yothers G et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29(28):3768-74. Abstract